SL

Simulations Plus IncNASDAQ SLP Stock Report

Last reporting period 31 May, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

0.627

Micro

Exchange

XNAS - Nasdaq

SLP Stock Analysis

SL

Neutral

Based on Eyestock quantitative analysis, SLP`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

86/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

32.5 %

Greatly undervalued

Market cap $B

0.627

Dividend yield

0.60 %

Shares outstanding

20.329 B

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 157 full-time employees. The firm provides prediction of properties of molecules utilizing both artificial intelligence (AI) and machine-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The company offers approximately 13 software products for pharmaceutical research and development, such as GastroPlus, DDDPlus, MembranePlus, ADMET Predictor, MedChem Designer, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite and PKPlus. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and academic and regulatory agencies worldwide for use in the conduct of industry-based research. Its subsidiaries include Cognigen Corporation, DILIsym Services, Inc. and Lixoft.

View Section: Eyestock Rating